explore -WSS

explore

author：hotspot 2025-10-02 21:04:40 - browse：751

Eli Lilly headquarters in Indianapolis – pharmaceutical coverage from STAT — Darron Cummings/AP

Scientists at the Food and Drug Administration have two big questions about Eli Lilly’s experimental Alzheimer’s drug donanemab ahead of a panel of outside experts that it is convening on Monday:

Should the patients who receive the medicine be limited based on PET scans of a protein called tau that Eli Lilly used as a key criteria for trying to determine whether they should receive the drug? That could reduce usage of the medicine by adding a barrier to its use.

And how do the potential risks of using the drug compare to its benefits? The FDA points to one analysis, admittedly with missing data, that could indicate patients who receive the drug have a higher risk of dying.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Psychedelics group wrestles with new pharma identity
Next article： Undocumented workers face uncertainty as immigration law takes effect in Florida

leisure time

WSS

Cassava reveals details — and problems — with Alzheimer's study

FDA approves Eli Lilly ulcerative colitis treatment Omvoh

Use doctors trained outside the U.S. to ease the physician shortage

Diversifying clinical trials isn't enough to close racial gaps: study

Crowdfunding for unproven stem cell procedures spreads misinformation

Physician subsidies by hospitals soar in wake of No Surprises Act

Wikipedia

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

knowledge

DIEP, the 'gold standard' of breast reconstruction, is under threat

Readout Newsletter: XBI biotech index, Akero Therapeutics

Hepatitis C has a cure — but many Americans still lack access to it

Cassava reveals details — and problems — with Alzheimer's study

Virginia high school admissions case could be legal follow

Use doctors trained outside the U.S. to ease the physician shortage

Affirmative action in medical school literally saved lives

STAT wants to know your pick for a great summer read or listen

Continuity nursing helped my family in our darkest PICU moments

Undocumented workers face uncertainty as immigration law takes effect in Florida

Wikipedia

Fatty liver disease was alleviated by Lilly’s ‘triple

WHO may add ‘noma' to its list of neglected tropical diseases

How Robert F. Kennedy Jr. distorted vaccine science

Skip the lead apron during X

Diversifying clinical trials isn't enough to close racial gaps: study

'Screen and refer' systems are hurting patients

hotspot

entertainment

leisure time

hotspot